Uncategorized

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment – CNBC

Posted on Author Tim Hodges Comments Off on FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment – CNBC
  1. FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment  CNBC
  2. Johnson & Johnson Gets FDA OK For Spravato as Monotherapy  MarketWatch
  3. J&J stock in focus after Spravato label expansion (JNJ:NYSE)  Seeking Alpha
  4. US FDA approves J&J’s ketamine-based therapy to treat depression  Reuters.com
  5. FDA approves SPRAVATO as first monotherapy for MDD  Investing.com India